ADMA Biologics Inc (NASDAQ:ADMA) has coverage initiated with a Buy rating and $8.00 price target

ME Staff
-
0

Analyst Ratings For ADMA Biologics Inc (NASDAQ:ADMA)

Today, Jefferies Financial Group initiated coverage on ADMA Biologics Inc (NASDAQ:ADMA) with a Buy with a price target of $8.00.

There are 8 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.

The current consensus rating on ADMA Biologics Inc (NASDAQ:ADMA) is Buy with a consensus target price of $10.9286 per share, a potential 158.36% upside.

Some recent analyst ratings include

  • 6/4/2019-ADMA Biologics Inc (NASDAQ:ADMA) has coverage initiated with a Buy rating and $8.00 price target
  • 10/12/2018-ADMA Biologics Inc (NASDAQ:ADMA) had its Buy rating reiterated by Raymond James with a $10.00 price target
  • 7/30/2018-ADMA Biologics Inc (NASDAQ:ADMA) has coverage initiated with a Buy rating and $10.00 price target
  • On 5/21/2019 Life Sciences Maste Perceptive, Major Shareholder, bought 4,000,000 with an average share price of $4.00 per share and the total transaction amounting to $16,000,000.00.
  • On 5/17/2019 Adam S Grossman, Insider, bought 30,000 with an average share price of $4.00 per share and the total transaction amounting to $120,000.00.
  • On 5/17/2019 Brian Lenz, CFO, bought 5,000 with an average share price of $4.00 per share and the total transaction amounting to $20,000.00.
  • On 5/17/2019 James Mond, EVP, bought 4,500 with an average share price of $4.00 per share and the total transaction amounting to $18,000.00.
  • On 5/17/2019 Lawrence P Guiheen, Director, bought 25,000 with an average share price of $4.00 per share and the total transaction amounting to $100,000.00.
  • On 6/8/2018 Adam S Grossman, CEO, bought 52,301 with an average share price of $4.78 per share and the total transaction amounting to $249,998.78.
  • On 6/8/2018 Brian Lenz, CFO, bought 5,000 with an average share price of $4.78 per share and the total transaction amounting to $23,900.00.

About ADMA Biologics Inc (NASDAQ:ADMA)
ADMA Biologics, Inc, a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease. Read More…

Recent Trading Activity for ADMA Biologics Inc (NASDAQ:ADMA)
Shares of ADMA Biologics Inc closed the previous trading session at 4.23 up +0.030 0.71% with 4.15 shares trading hands.